PepEvolutionGHRP-2
A PMDA-approved (Japan) diagnostic GH secretagogue with more cortisol/prolactin elevation than Ipamorelin.
Verdict — C · Emerging / Mixed
PMDA-approved as a diagnostic with moderate human evidence. More cortisol and prolactin co-stimulation than Ipamorelin makes it a second-choice GHRP for most buyers. Prefer Ipamorelin for cleaner secretagogue support unless cost or availability is a constraint.
Overview
GHRP-2 is a second-generation ghrelin-mimetic GH secretagogue, approved in Japan (PMDA, 2004) as a diagnostic agent for GH deficiency assessment. It produces a robust GH pulse with meaningful cortisol and prolactin co-stimulation, distinguishing it from the more selective Ipamorelin. Human data exist primarily from the diagnostic indication and from gray-market use documentation; moderate gray-market availability is offset by the side-effect profile.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Want a clinical path?
Talk to a licensed provider about GHRP-2 and whether it's appropriate for your situation.
Talk to a Provider ↗Telehealth. Not medical advice — for educational purposes.
Get the PepEvolution Dispatch
Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.
Free. Unsubscribe anytime. Research/educational content only.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.